Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Next Previous
Search
Trial Profile

Chemotherapy Plus Lapatinib or Trastuzumab or Both in Her2+ Primary Breast Cancer. A Randomized Phase IIb Study With Biomarker Evaluation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Methotrexate; Paclitaxel; Trastuzumab
  • Indications Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms CHER-LOB
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 07 Sep 2023 Results from ShortHER trial, CherLOB , evaluating how molecular heterogeneity affects the pattern of distant relapse in HER2-positive BC, published in the Journal of the National Cancer Institute
  • 18 Jun 2021 Results of post-hoc survival analysis assessing long-term survival outcomes published in the European Journal of Cancer
  • 31 May 2020 Primary endpoint (Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes) has been met, as per Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top